{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:17Z","timestamp":1790803697301,"version":"4.1.0"},"reference-count":9,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respiration"],"abstract":"<jats:p>&lt;p&gt;Introduction: Cystic fibrosis (CF) is associated with a high respiratory symptom and treatment burden. Elexacaftor\/tezacaftor\/ivacaftor (ETI) provides substantial improvements in physiological outcomes such as respiratory function and sweat chloride. This study sought to comprehensively examine an area of limited research in this field: the lived experiences of adults with CF after ETI initiation. Methods: Adults with CF completed semi-structured interviews at least 6 weeks following the initiation of ETI. Participants shared their experiences regarding respiratory-related symptoms, airway clearance routines, and their capacity to participate in physical activity. Interviews were audio-recorded, transcribed verbatim and analysed using the Framework Method. Results: Seventeen participants completed interviews (FEV&lt;sub&gt;1&lt;\/sub&gt; range before ETI initiation 31 to 87 % predicted). All participants reported improvements in respiratory-related symptoms including cough, sputum expectoration, dyspnoea, and chest tightness. As a result, there was a reduction in participants airway clearance treatment burden and improvements in their capacity to participate in physical activity, health-related quality of life and outlook for the future. The overall theme highlighted in this study was that ETI had \u201ccompletely changed everything\u201d and they can now do \u201ceverything I wasn\u2019t able to do before\u201d due to the reductions in symptom and treatment burden. Conclusion: Participants consistently described their experiences with ETI in positive terms. The results of this study confirm that ETI is in fact perceived to be a \u201cmiracle drug\u201d and has had a transformative effect on the everyday lives of adults with CF through improved HRQoL and overall wellbeing, which led to positive views regarding their future with CF and ongoing medical care. &lt;\/p&gt;<\/jats:p>","DOI":"10.1159\/000549098","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:01:28Z","timestamp":1761235288000},"page":"454-469","source":"Crossref","is-referenced-by-count":1,"title":["\u201cAn Amazing Transformation!\u201d The Lived Experiences of Elexacaftor\/Tezacaftor\/Ivacaftor in Adults with Cystic Fibrosis"],"prefix":"10.1159","volume":"105","author":[{"given":"Naomi","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sona","family":"Vekaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6082-6352","authenticated-orcid":false,"given":"Kylie","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Cavalheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhain","family":"Mulrennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Gucciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-117"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0002"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2014.09.018"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19106114"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201009-1478CI"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/17423953221099042"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1037\/qup0000196"}],"container-title":["Respiration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000549098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:01:36Z","timestamp":1776441696000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000549098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":9,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,17]]},"published-print":{"date-parts":[[2026,4,15]]}},"URL":"https:\/\/doi.org\/10.1159\/000549098","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.30414895","asserted-by":"subject"}]},"ISSN":["0025-7931","1423-0356"],"issn-type":[{"value":"0025-7931","type":"print"},{"value":"1423-0356","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}